A fast-screening dispersive liquid-liquid microextraction-gas chromatography-mass spectrometry method applied to the determination of efavirenz in human plasma samples.
DLLME
Efavirenz
GC–MS
LLOQ
Therapeutic drug monitoring
USFDA
Journal
Analytical and bioanalytical chemistry
ISSN: 1618-2650
Titre abrégé: Anal Bioanal Chem
Pays: Germany
ID NLM: 101134327
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
23
05
2021
accepted:
05
08
2021
revised:
14
07
2021
pubmed:
25
9
2021
medline:
15
12
2021
entrez:
24
9
2021
Statut:
ppublish
Résumé
We demonstrate the suitability of a fast, green, easy-to-perform, and modified sample extraction procedure, i.e., dispersive liquid-liquid microextraction (DLLME) for the determination of efavirenz (EFV) in human plasma. Data acquisition was done by gas chromatography-mass spectrometry (GC-MS) in the selected ion monitoring (SIM) mode. The simplicity of the method lies in, among others, the avoidance of the use of large organic solvent volumes as mobile phases and non-volatile buffers that tend to block the plumbing in high-performance liquid chromatography (HPLC). Chromatographic and mass spectral parameters were optimized using bovine whole blood for matrix matching due to insufficient human plasma. Method validation was accomplished using the United States Food and Drug Administration (USFDA) 2018 guidelines. The calibration curve was linear with a dynamic range of 0.10-2.0 μg/mL and an R
Identifiants
pubmed: 34557941
doi: 10.1007/s00216-021-03604-0
pii: 10.1007/s00216-021-03604-0
doi:
Substances chimiques
Alkynes
0
Anti-Bacterial Agents
0
Benzoxazines
0
Cyclopropanes
0
Reverse Transcriptase Inhibitors
0
Metronidazole
140QMO216E
efavirenz
JE6H2O27P8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6401-6412Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Neogi U, Häggblom A, Singh AK, Rogers LC, Rao SD, Amogne W, Schülter E, Zazzi M, Arnold E, Sarafianos SG, Sönnerborg A. Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. J Antimicrob Chemother. 2016;71(2):367–71. https://doi.org/10.1093/jac/dkv359 .
doi: 10.1093/jac/dkv359
pubmed: 26518047
Hemelaar J, Gouws E, Ghys PD, et al. Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS. 2011;25:679–89. https://doi.org/10.1097/QAD.0b013e328342ff93 .
doi: 10.1097/QAD.0b013e328342ff93
pubmed: 21297424
The NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-doseefavirenz–based regimen for the treatment of HIV-1. N Engl J Med. 2019;381:816–26. https://doi.org/10.1056/NEJMoa1904340 .
doi: 10.1056/NEJMoa1904340
World Health Organization. (WHO) (2019) Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO. Last Accessed 29
Hartman TL, Buckheit RW. The continuing evolution of HIV-1 therapy: identification and development of novel antiretroviral agents targeting viral and cellular targets. Mol Biol Int J. 2012;401965. https://doi.org/10.1155/2012/401965 .
Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Intern AIDS Soc. 2011;14:15–27. https://doi.org/10.1186/1758-2652-14-15 .
doi: 10.1186/1758-2652-14-15
Arendt G, De-Nocker D, Von-Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007;6:147–54. https://doi.org/10.1517/14740338.6.2.147 .
doi: 10.1517/14740338.6.2.147
pubmed: 17367260
Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, Carey PB, Khoo SH. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. J Clin Infect Dis. 2010;50:1419–21. https://doi.org/10.1086/652149 .
doi: 10.1086/652149
Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV. New Engl J Med. 2006;354:251–60. https://doi.org/10.1056/NEJMoa051871 .
doi: 10.1056/NEJMoa051871
pubmed: 16421366
Russo G, Paganotti GM, Soeria-Atmadja S, Haverkamp M, Ramogola-Masire D, Vullo V, Gustafsson LL. Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments. Infect Genet Evol. 2016;37:192–207. https://doi.org/10.1016/j.meegid.2015.11.014 .
doi: 10.1016/j.meegid.2015.11.014
pubmed: 26602158
Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV. Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. 2015;70:2693–708. https://doi.org/10.1093/jac/dkv183 .
doi: 10.1093/jac/dkv183
pubmed: 26203180
Donnerer J, Kronawetter M, Kapper A, Haas I, Kessler HH. Therapeutic drug monitoring of the HIV / AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Aust J Pharm. 2003;69:197–204. https://doi.org/10.1159/000073664 .
doi: 10.1159/000073664
Langmann P, Zilly M, Weissbrich B, Desch S, Väth T, Klinker H. Therapeutic drug monitoring of Indinavir in HIV-infected patients undergoing HAART. J Infect Dis. 2002;30:13–6. https://doi.org/10.1007/s15010-001-1111-0 .
doi: 10.1007/s15010-001-1111-0
Rezk NL, Tidwell RR, Kashuba ADM. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B. 2004;805:241–7. https://doi.org/10.1016/j.jchromb.2004.03.002 .
doi: 10.1016/j.jchromb.2004.03.002
Sarasa-Nacenta M, Lopez-pua Y, Lopez-Cortes LF, Mallolas J, Gatell JM, Carne X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 2001;763:53–9. https://doi.org/10.1016/s0378-4347(01)00357-7 .
doi: 10.1016/s0378-4347(01)00357-7
Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B. 2004;813:353–8. https://doi.org/10.1016/j.jchromb.2004.10.005 .
doi: 10.1016/j.jchromb.2004.10.005
Ramachandran G, Kumar AKH, Swaminathan S, Venkatesan P, Kumaraswami V, Greenblatt DJ. Simple and rapid liquid chromatography method for determination of efavirenz in plasma. J Chromatogr. 2006;835(2006):131–5. https://doi.org/10.1016/j.jchromb.2006.03.014 .
doi: 10.1016/j.jchromb.2006.03.014
Fox D, Connor RO, Mallon P, Mcmahon G. Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma. J Pharmaceut Biomed Anal. 2011;56:785–91. https://doi.org/10.1016/j.jpba.2011.07.041 .
doi: 10.1016/j.jpba.2011.07.041
Hoffman JT, Rossi SS, Espina-Quinto R, Letendre S, Capparelli EV. Determination of efavirenz in human dried blood spots by reversed-phase high-performance liquid chromatography with UV detection. J Ther Drug Monit. 2013;35:203–8. https://doi.org/10.1097/FTD.0b013e31827fb72b .
doi: 10.1097/FTD.0b013e31827fb72b
Ren C, Fan-Havard P, Schlabritz-Loutsevitch N, Ling Y, Chan KK, Liu Z. A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons. J Biomed Chromatogr. 2009;24:717–26. https://doi.org/10.1002/bmc.1353 .
doi: 10.1002/bmc.1353
Theron A, Cromarty D, Rheeders M, Viljoen M. Determination of salivary efavirenz by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B. 2010;878:2886–90. https://doi.org/10.1016/j.jchromb.2010.08.051 .
doi: 10.1016/j.jchromb.2010.08.051
Zhang L, Sun J, Chen J, Jia XF, Shen F, Lu HZ. An LC–MS/MS method for simultaneous quantification of seven anti-HIV medicines in plasma of HIV-infected patients. Pharm Anal Acta. 2010;1:102. https://doi.org/10.4172/2153-2435.1000102 .
doi: 10.4172/2153-2435.1000102
Soldin SJ, Soukhov N, Janici N, Jonklaas J, Soldin OP. The measurement of free thyroxine by isotope dilution tandem mass spectrometry. Clin Chimica Acta. 2005;358:113–8. https://doi.org/10.1016/j.cccn.2005.02.010 .
doi: 10.1016/j.cccn.2005.02.010
Sichilongo K, Mwando E, Sepako E, Massele A. Comparison of efficiencies of selected sample extraction techniques for the analysis of selected antiretroviral drugs in human plasma using LC-MS. J Pharmacol Toxicol Methods. 2018;89:1–8. https://doi.org/10.1016/j.vascn.2017.10.001 .
doi: 10.1016/j.vascn.2017.10.001
pubmed: 28989077
Srivastava P, Moorthy GS, Gross R, Barrett JS. A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma. PLoS One. 2013;8:1–9. https://doi.org/10.1371/journal.pone.0063305 .
doi: 10.1371/journal.pone.0063305
Rouzes A, Karine B, Xuere F, Djabarouti S, Pellegrin I, Pellegrin JL, Coupet AC, Augagneur, Budzinski H, Saux MC, Breilh D. Simultaneous determination of the antiretroviral agents: amprenavir , lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography – mass spectrometry. J Chromatogr B. 2004;813:209–16. https://doi.org/10.1016/j.jchromb.2004.09.041 .
doi: 10.1016/j.jchromb.2004.09.041
Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin EST, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22:3401–9. https://doi.org/10.1002/rcm.3750 .
doi: 10.1002/rcm.3750
pubmed: 18837069
pmcid: 2669487
Lemmer P, Schneider S, Schuman M, Omes C, Arendt V, Tayari JC, Fundira L, Wennig R. Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode. J Ther Drug Monit. 2002;27:521–5. https://doi.org/10.1097/01.ftd.0000164613.91555.2e .
doi: 10.1097/01.ftd.0000164613.91555.2e
González O, Alonso RM. Validation of bioanalytical chromatographic methods for the quantification of drugs in biological fluids. Handbook of Analytical Separations. 2020;7:115–34.
doi: 10.1016/B978-0-444-64066-6.00006-X
Ridgway K (2019). https://www.anatune.co.uk/wp-content/uploads/2019/04/AS224-Automated-solvent-extraction-LLME-and-DLLME-of-Flavours-from-a-selection-of-fruit-beverages.pdf last accessed 3
USFDA (2018). Bioanalytical method validation guidance for industry, https://www.fda.gov/media/70858/download last accessed 7th august 2020.
Azadeh M, Gorovits B, Kamerud J, MacMannis S, Safavi A, Sailstad J, Sondag P. Calibration curves in quantitative ligand binding assays: recommendations and best practices for preparation, design, and editing of calibration curves. AAPS J. 2018;20:22. https://doi.org/10.1208/s12248-017-0159-430 .
doi: 10.1208/s12248-017-0159-430
Cheng CL, Chou CH, Yoa-Pu Huc O. Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. J Chromatogr B. 2005;817:199–206. https://doi.org/10.1016/j.jchromb.2004.12.004 .
doi: 10.1016/j.jchromb.2004.12.004
Cheng CL, Chou CH, Yoa-Pu Huc O. Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B. 2002;769:297–303. https://doi.org/10.1016/S1570-0232(02)00015-6 .
doi: 10.1016/S1570-0232(02)00015-6
Heydari R, Rashidipour M, Naleini N. Determination of efavirenz in plasma by dispersive liquid-liquid micro-extraction coupled to high-performance liquid chromatography. Current Anal Chem. 2014;10:280–7. https://doi.org/10.2174/15734110113099990003 .
doi: 10.2174/15734110113099990003
Polson C, Sarkar P, Incledon B, Raguvaran V, Grant R. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography– tandem mass spectrometry. J Chromatogr B. 2003;785:263–75. https://doi.org/10.1016/S1570-0232(02)00914-5 .
doi: 10.1016/S1570-0232(02)00914-5
Toribio-Delgado AF, Robles-Gil MC, Maynar-Mariño M, Olcina-Camacho G, Maynar-Mariño JI. Is deproteinization necessary in the determination of human plasmatic steroids by GC/IT-MS/MS analysis? J Applied Bioanal. 2015;1:10–8. https://doi.org/10.17145/jab.15.003 (ISSN 2405-710X).
doi: 10.17145/jab.15.003
Wisconsin Department of Natural Resources Laboratory Certification Program (1996) Analytical detection limit guidance & laboratory guide for determining method detection limits. https://dnr.wi.gov/regulations/labcert/documents/guidance/-LODguide.pdf Last Accessed 8
Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC - MS / MS. Intern J Anal Chem. 2003;75:3019–30. https://doi.org/10.1021/ac020361s .
doi: 10.1021/ac020361s
Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD. Efavirenz therapeutic range in HIV-1 treatment-naive participants. Ther Drug Monit. 2017;39:596–603. https://doi.org/10.1097/FTD.0000000000000443 .
doi: 10.1097/FTD.0000000000000443
pubmed: 29135907
pmcid: 5718358
Kankaanpää A, Turtiainen S, Meririnne E, Ariniemi K, Ristola M, Kuoppasalmi K. Determination of the non-nucleoside reverse transcriptase inhibitor efavirenz in human plasma by gas chromatography mass spectrometry. Ther Drug Mont. 2007;29:513–4.